Stevanato Group S.p.A. (STVN), an Italian provider of industrial drug containment, drug delivery, and diagnostic solutions, on Wednesday initiated guidance for the full year.
For fiscal 2026, the company expects adjusted profit of €0.59 to €0.63 per share, with adjusted EBITDA of €331.8 million to €346.9 million, on revenue of €1.26 billion to €1.29 billion.
For fiscal 2025, the Group has reported adjusted profit of €0.54 per share, with adjusted EBITDA of €298 million, on revenue of €1.186 billion.
STVN was up by 5.09% at $15.48 in the pre-market trade on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.